Our research team, initially established to provide support to improve and optimise production and control processes, has broadened into designing its own research programs, incorporating the infrastructures required for these ends.

Its division into separate areas such as chemical synthesis, proteomics and molecular biology are primarily involved in the application of avant-garde technologies such as in-situ hybridisation and chromatography techniques as foundations for its programs, with the cooperation of universities including the Universidad de Alcalá in Madrid, the Universidad Autónoma in Barcelona and Málaga and Louisiana State University in New Orleans, USA; as well as institutions such as the FEHV (Foundation for the Study of Viral Hepatitis) in Madrid.

The basis for the action plans is the production of forms of recombinant allergens and the isolation of clinically relevant native allergens of the chief allergens and of different allergy sources such as fungus, mites and pollen found in different pre-clinical and clinical phases with the intention of incorporating them not only into the diagnosis but to evaluate the therapeutic effectiveness in different clinical trials involving different administration methods in inmunotherapy with allergens. Other programs include the synthesis, clogging and blockage of allergenic determinants of β-lactam antibiotics that could improve the knowledge and diagnosis of sensibility to this type of medications. Lastly, a new application of the team is considering the design of new alternatives through in vitro diagnosis of the ¨hidden¨ hepatitis C virus.

These programs have it made possible to bring about their incorporation in different research plans of the CAM, and nationally in plans such as PROFIT. As well as in policymaking alongside public organizations such as CDTI, which guarantees interest and support.